News Briefs

Merck & Co., Inc. will voluntarily withdraw the accelerated approval indication for Keytruda (pembrolizumab) for the treatment of people with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express programmed death-ligand 1 (PD-L1), as determined by an FDA-approved test, with disease progression on or after at least two lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate, human epidermal growth factor receptor 2 (HER2)/neu-targeted therapy. The move follows the April 29 Oncologic Drugs Advisory Committee meeting in which members voted against keeping the indication after late-stage confirmatory trials did not show clinical benefit. Merck says it will begin the withdrawal in six months.

The expected average cost of new FDA-approved specialty drugs in 2020 was just under $350,000 per year. That was one of the findings of analytics company AMS’s 2020 Specialty Drug Trends Report, based on drugs added to the firm’s PredictRx module, which incorporates pertinent clinical information and AMS Cost Projection (ACP) pricing. It also found that the average yearly cost for newly approved orphan drugs was $449,507, compared with $144,130 for traditional drugs.

© 2024 MMIT
Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

stethoscope-on-cash
March 14

Cardinal Health Report Highlights ‘Pivotal Year’ for Biosimilars

READ MORE
pills-in-dollar-sign
March 14

COA: New Part D Reimbursement Is Not ‘Reasonable and Relevant’

READ MORE
bill-and-pill
March 14

FDA Grants Full Approval to Game-Changing Regimen for Urothelial Cancer

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today